12:00 AM
May 28, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Amatuximab: Interim Phase II data

Interim data from the open-label, international Phase II MORAb-009-003 trial in 89 chemotherapy-naïve patients with unresectable epithelial or biphasic pleural MM showed that 5 mg/kg amatuximab on days 1 and 8 of a 21-day cycle in combination with...

Read the full 170 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >